SynthesisBMC infectious diseases2026
Clinical effectiveness of three months once-weekly Isoniazid and Rifapentine regimen for treatment of Latent TB Infection: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlobally, multiple TB preventive treatment (TPT) regimens are available for Latent Tuberculosis Infection (LTBI) and implementing TPT is essential for achieving TB elimination. Standard treatments for LTBI include 9 and 6-month isoniazid monotherapy (9H and 6H) regimens, recent clinical trials also introduced the shorter once-weekly 3-month isoniazid plus rifapentine (3HP) regimen. To evaluate the clinical effectiveness of 3HP in adults, we performed a comprehensive synthesis on the clinical effectiveness (treatment completion, adverse drug reactions (ADRs) and exploratory analysis of incident active TB) of the 3HP regimen compared with 9H and 6H.
methodsA systematic search was carried out in PubMed, EMBASE, ScienceDirect, and Cochrane Library. An excel data collection tool was used for collecting the required data. Pooled estimates of effectiveness were calculated through random-effects meta-analysis model using odds ratio (OR) and risk ratio (RR) as summary measures. Risk of bias was assessed using the RoB 2.0 and ROBINS-I tools, and publication bias was evaluated. The certainty of the evidence was assessed using the GRADE approach.
resultsTwenty studies met eligibility criteria, of which 5 were trials and 15 were observational studies. Meta-analysis showed that participants receiving the 3HP regimen were nearly three times more likely to complete treatment compared to 9H regimen (OR = 2.81; 95% CI: 2.05-3.86; low certainty) and the OR was 2.91 compared to 6H regimen. The risk of ADRs was 1% higher with 3HP when compared to 9H (RR = 1.01; 95% CI: 0.76-1.33; very low certainty). The pooled RR of adverse events, such as grade 1-2, grade 3-4, grade 5 and hepatotoxicity were 1.38 (95% CI: 0.73-2.59; I
conclusionThe shorter 3HP regimen is associated with higher treatment completion and lower hepatotoxicity compared to 9H, with evidence on progression to active TB remains exploratory and imprecise. Limited evidence on 6H showed improved treatment completion with 3HP. These findings should be interpreted cautiously as most evidence was derived from heterogeneous observational studies, and the certainty of evidence for main outcomes was low to very low. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.